CERA Solutions Competitors

Oracle Health strives to connect providers, patients, and public health and life sciences organizations by leveraging the power of data. We aim to create a human-centered healthcare experience for patients—and help physicians reclaim the joy of medicine. For more than 45 years, Oracle has led the way in modern data management and intelligence solutions supporting the healthcare community. Through ground-breaking research and clinical trials, we’ve helped improve efficiency and reduce costs with our industry-leading Cloud infrastructure, database, and front- and back-office applications. We received the 2024 Best in KLAS award for our acute care EMR. By harnessing Oracle’s most valuable asset - data - we develop interoperable, cloud-native applications across areas like genomics, virtual care, and extending electronic health record systems with AI and machine learning.

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is in late-stage clinical development. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

CeramTec UK is affiliated with the German ceramic giant CeramTec AG, and both companies’ roots are an integral part of the global history of technical ceramics. This history includes more than 115 years of manufacturing by our parent company as well as more than 40 years from the origin of our Colyton operations in Devon, UK. Few ceramic companies offer such a strong heritage. Thus, solutions for the materials of the future are based on the two pillars of experience and R&D: comprehensive experience in the possibilities and areas of application on the one hand, and constant application-oriented research and development work on the other. The companies in the CeramTec Group supply products for almost every area of living, working, and technology, often unseen, but almost always indispensable. As a pioneer in the conception of new solutions for ever wider and more sophisticated areas of use for ceramics, CeramTec keeps setting new standards in the area of high-performance ceramics. In 1996, the formal merger of Hoechst CeramTec and Dynamit Nobel’s Cerasiv Division created “CeramTec”. In 2004, CeramTec was acquired by Rockwood Specialties, playing a key part in this leading specialty chemicals/advanced materials company’s portfolio. CeramTec UK has one manufacturing facility (Colyton, Devon) totaling 9,300 square meters of manufacturing space. Our UK operation is among the ten CeramTec facilities of our parent company located throughout Asia, Europe, and the United States. Consistent development of new materials, high levels of quality, concentration on customer-specific system solutions, and dialog-oriented application consultancy over the product’s entire lifecycle are the critical ingredients for our success.